UTv Videos

“What our studies were looking at was a novel device that could potentially help bridge the gap between [endoscopic treatment and urethroplasty] to achieve endoscopic treatment and achieve greater success,” says Justin Chee, MD.

“Doing this study allows us to say, 'With repeat treatments, we're not seeing a greater risk of retention, and we're not seeing a greater risk of UTI,'" says David A. Ginsberg, MD.

“I think that a lot of the best practices that the surgeons had developed and honed were really excellent communication skills, and…building a trusting physician-patient relationship, where they truly provided an informed consent of all the risks, all the benefits, [and] all the alternatives,” says Una Lee, MD, FPMRS.

“[Attendees] will be learning multiple aspects in terms of the genetic evaluation for men with prostate cancer,” says Veda N. Giri, MD.

Welcome to another installment of Uranimals, a video series featuring urologists and their pets, brought to you by urology times. From a snuggling cat companion to an Australian parakeet, we have some more great guests for you!

“The main advantages with regard to the Zenflow Spring System are that there's no piercing, there's no trauma, and there's no heat involved with the treatment,” says Peter Chin, MD.

“Bottom line, there's really no way to separate all of the things that we do, but I think we can all be more conscious on a day-to-day basis in terms of our own environmental footprint and just making better choices,” says Stacy Loeb, MD, PhD, MSc.

By identifying trends in race and ethnicity of academic urologists, this study poses as an opportunity for future intervention.

“Ideally…we have a technology that's noninvasive that we can use in the clinic, where they don't require any anesthesia to…break the stones and make them smaller,” says Mathew D. Sorensen, MD, MS, FACS.

“The data…showed us that a lot of young [men]…are coming in for ED, and we can't really think of it as just a disease of older men…It can affect you at any age,” says Denise Asafu-Adjei, MD, MPH.

“This study was very important in that it showed cost savings with MOSES as well as the ability to reliably achieve same-day discharge,” says Matthew S. Lee, MD.

“I think the surgeon voice is an important voice to be heard because there's not a lot of avenues for surgeons to be able to be honest and share all the things they've learned and all the things they've experienced with their patients,” says Una Lee, MD, FPMRS.

“In short, there's a ton of missed opportunity to see how smoking affects treatments, especially in trial patients, and even in our patients that are in our clinics,” says Richard Matulewicz, MD, MS.

As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on,” says Anne M. Suskind, MD, MS, FACS, FPMRS.

“One of the study findings that really stood out to me was that so many of the surgeons that we spoke to are…such strong advocates for their patients,” says Wai Lee, MD.

“Even factoring in the increased number of emergency room visits, there was still an overall cost savings of $747 in favor of the Moses HoLEP. So, that was surprising to see,” says Matthew S. Lee, MD.

"The focus of this study and the patient cohort that we're looking at are patients with intermediate-risk bladder cancer who [also have] low-grade bladder cancer. These patients [typically have] a lot of recurrences [and] multi-focal disease but are at low risk of progressing on to metastatic disease or developing invasion into their bladder wall,” says William C. Huang, MD.

“The world's a very, very small place and there are a lot of people who are hurting. It's our job as physicians to help relieve that discomfort, wherever it may exist, whether it's here in the United States or elsewhere, and this is the device that allows that to be realized,” says Ralph V. Clayman, MD.

“The concept behind the NAXIVA trial was to treat these patients with pre-surgical neoadjuvant targeted therapy with a means of downstaging that venous tumor thrombus, reducing the extent of it to try and make the surgery less morbid to the patient and to potentially improve survival,” says Grant Stewart, MD.

“It is a vaccine that is self-administered by the patient sublingual over 3 months, and that is why it appears to be so safe,” says J. Curtis Nickel, MD.

“This study really demonstrates, for one of the first times certainly in the largest cohort of men ever [studied], that Rezum water vapor thermal therapy is a viable option to treat men with very large prostates bigger than 80 mL,” says Dean Elterman, MD, MSc, FRCSC.

“The take-home message is vibegron is a very safe drug and there are no concerns about any kind of cardiovascular adverse effects,” says Michael A. Weber, MD.

“I want to reiterate that this study doesn't necessarily say that 1 approach is better than the other, but it definitely does reinforce some advantages of robotic surgery that have been shown not just in this study, but in other studies as well,” says Peter Chang, MD, PhD.

“[We gave the ES kits out] with the idea that instead of having these people…travel…hundreds of miles to a main hospital for their endoscopy, the urologist could travel to a village with just the smartphone and the endoscope set-up and proceed to do a ton of endoscopy there,” says Ralph V. Clayman, MD.

"This work isn't for one; it is certainly for all,” says Efe C. Ghanney Simons, MD.

“Rather than asking the staff to have a stiff upper lip and cope, we instead tried to focus on uncovering systemic processes that were ripe for change,” says Loren Jean Smith.

“The quality of life overall between the 2 approaches was very similar,” says Peter Chang, MD, PhD.

“The data is out to about 2 to 3 years now, so…[it’s] a little bit on the immature side, but it's very promising,” says Bilal Chughtai, MD.